Dihexa acetate dropped off the FDA's Category 2 restricted list on April 22, 2026, as part of the agency's 12-peptide reclassification action. A Pharmacy Compounding Advisory Committee review is scheduled before February 2027. But anyone reading that headline needs to know what's underneath it — because the foundational science behind dihexa comes with a $4 million False Claims Act settlement.
Research-context information only. Peptides discussed below are research compounds. Protocols, doses, and reactions reported come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
What Changed on April 22
The FDA published its 503A Categories Update on April 15 removing 12 peptides from Category 2. Dihexa acetate is one of them. The removal took effect seven days later, on April 22. Dihexa is now scheduled for PCAC review before the end of February 2027, alongside four other peptides: LL-37, GHK-Cu, PEG-MGF, and Melanotan II.
Removal from Category 2 is not the same as approval. It means the agency no longer has an active nomination designating dihexa as posing "significant safety concerns." That happened because the original nominator voluntarily withdrew their petition. The peptide now sits in a regulatory gray zone — not restricted, not approved, waiting for a formal PCAC vote.
The April 22 date matters for one reason: before it, compounding pharmacies had an explicit legal citation to refuse dihexa prescriptions. After it, that citation is gone. Most pharmacies will still wait for the PCAC vote before actually compounding, but the legal scaffolding for blanket refusal has been removed.
The Credibility Problem Nobody Mentions
Dihexa — short for N-hexanoic-Tyr-Ile-(6) aminohexanoic amide — was developed at Washington State University in the lab of Joseph Harding. A spinoff company, Athira Pharma (formalized as M3 Biotechnology before rebranding), was founded in 2011 by PhD student Leen Kawas to commercialize dihexa and a related molecule, ATH-1017 (fosgonimeton). Kawas served as CEO until 2021.
In 2021, Athira's board placed Kawas on leave after allegations emerged that she had manipulated images in her doctoral dissertation and in published research papers. Those papers — which formed the preclinical rationale for dihexa's nootropic claims and for Athira's NIH grant applications — had been cited as evidence that dihexa promoted synaptogenesis at rates far exceeding BDNF.
On January 6, 2025, the Department of Justice announced that Athira Pharma agreed to pay $4,068,698 to settle False Claims Act allegations. The settlement covered conduct between January 1, 2016 and June 20, 2021. Athira failed to disclose allegations of research misconduct to the National Institutes of Health in grant applications that referenced the manipulated papers, including a grant NIH funded in 2019. Four papers in the Journal of Pharmacology and Experimental Therapeutics received formal expressions of concern. A whistleblower, Andrew P. Mallon, received $203,434 for bringing the case.
That is the peer-reviewed evidence base for dihexa's cognitive effects. It is not destroyed — independent animal model work continues, and the HGF/c-Met mechanism has been corroborated by other labs — but the specific dramatic synaptogenesis claims that made dihexa famous (the "7x BDNF" numbers) trace back to papers now under formal expressions of concern by the journals that published them.
What This Means for Buyers
If you are researching dihexa right now, here is the practical picture.
No human clinical trials exist. Zero placebo-controlled human studies of dihexa have been published. Anecdotal reports describe pattern recognition and verbal fluency gains within 2-4 weeks at 5-10 mg subcutaneous protocols, but this is user-generated, not evidence. The related Athira compound fosgonimeton failed its Phase 2 Alzheimer's trial (LIFT-AD) in 2023 for efficacy, and Athira discontinued development.
It is not sold through telehealth or compounding pharmacies. Dihexa is not an approved drug. No licensed prescriber will write for it. No pharmacy will compound it. Everything you see advertised is research-grade material sold with a "research use only" label — the same category as BPC-157 and TB-500 before the April 22 Category 2 removal.
Oral forms are marketing, not science. Dihexa was designed specifically to survive first-pass metabolism better than parent angiotensin IV analogs, but most vendor oral capsule claims are not supported by peer-reviewed pharmacokinetic data in humans. Subcutaneous injection is the administration route used in all preclinical studies.
Quality and sourcing matter more than usual when the underlying science is contested. If the compound is going to have any chance of producing real effects, the material actually needs to be dihexa at the stated purity, not something adjacent or diluted. That means COA-verified vendors with recent third-party HPLC testing.
If You Are Still Buying — What to Compare
For research-use dihexa, the same vendor selection criteria that apply across peptides apply here: third-party COAs, reputation, peptide-specific pricing, and fulfillment consistency.
If Peptide Sciences was your prior source, they closed in March 2026 — see our Peptide Sciences alternatives comparison for the 7 vendors still shipping research peptides with COA documentation.
- Best peptide vendors 2026 — our current vendor rankings with COA verification
- Peptide purity testing guide — how to read HPLC certificates
- All peptide deals and coupon codes — current discount codes across recommended vendors
- Peptide coupon codes master list — stack discounts
For readers specifically interested in nootropic peptides with actual peer-reviewed human data, Semax and Selank have more rigorous evidence bases — see our Semax benefits article and Selank benefits article for the clinical literature.
